masitinib
-
AB10015, ALS, ALS survival, ALSFRS-R, amyotrophic lateral sclerosis, Drugs, ENCALS, masitinib, mast cells, microglia, motor neuron disease, Neurodegenerative Diseases, neuroscience, riluzole, tyrosine kinase inhibitorMasitinib for ALS: AB10015 Reports 42.3% 5-Year Survival
A 2026 AB10015 post-hoc preprint reported 42.3% 5-year survival from amyotrophic lateral…
